Current Oncology Reports最新文献_第3页

Artificial Intelligence and Cancer Health Equity: Bridging the Divide or Widening the Gap. 人工智能与癌症健康公平：弥合鸿沟还是扩大差距。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-02-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01627-1

Irene Dankwa-Mullan, Kingsley Ndoh, Darlington Akogo, Hermano Alexandre Lima Rocha, Sérgio Ferreira Juaçaba

{"title":"Artificial Intelligence and Cancer Health Equity: Bridging the Divide or Widening the Gap.","authors":"Irene Dankwa-Mullan, Kingsley Ndoh, Darlington Akogo, Hermano Alexandre Lima Rocha, Sérgio Ferreira Juaçaba","doi":"10.1007/s11912-024-01627-1","DOIUrl":"10.1007/s11912-024-01627-1","url":null,"abstract":"Purpose of review: This review aims to evaluate the impact of artificial intelligence (AI) on cancer health equity, specifically investigating whether AI is addressing or widening disparities in cancer outcomes.Recent findings: Recent studies demonstrate significant advancements in AI, such as deep learning for cancer diagnosis and predictive analytics for personalized treatment, showing potential for improved precision in care. However, concerns persist about the performance of AI tools across diverse populations due to biased training data. Access to AI technologies also remains limited, particularly in low-income and rural settings. AI holds promise for advancing cancer care, but its current application risks exacerbating existing health disparities. To ensure AI benefits all populations, future research must prioritize inclusive datasets, integrate social determinants of health, and develop ethical frameworks. Addressing these challenges is crucial for AI to contribute positively to cancer health equity and guide future research and policy development.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"95-111"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Management in Elderly Male Breast Cancer Patients: A Scoping Review. 老年男性乳腺癌患者的治疗管理：范围综述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-02-01 Epub Date: 2025-01-05 DOI: 10.1007/s11912-024-01629-z

Alessia Di Rito, Antonietta Grillo, Roberta Carbonara

{"title":"Therapeutic Management in Elderly Male Breast Cancer Patients: A Scoping Review.","authors":"Alessia Di Rito, Antonietta Grillo, Roberta Carbonara","doi":"10.1007/s11912-024-01629-z","DOIUrl":"10.1007/s11912-024-01629-z","url":null,"abstract":"Purpose of review: Male breast cancer (MBC) is a rare entity which often arises in elderly people. Aim of this review is to evaluate the principal issues related to MBC in elderly, because the therapeutic management of disease is not only related to the biological behavior of the tumor, but also to the comorbidities and frailty of older population. A scoping literature review was performed on Pubmed and Cochrane Database using the following keywords: therapeutic management/ male/ breast cancer/ elderly patients. Papers published before 2000, not edited in English or French language, or not related to the main topic, were excluded. Only articles related to therapeutic issues in MBC and including more than 10 elderly (≥ 65 years) patients were selected for the qualitative outcome analysis.Recent findings: 36 papers regarding surgery, radiotherapy, systemic therapy, racial disparities and therapeutic management in retrospective series of MBC in elderly were examined in details. MBC has a different biological behavior and a poorer prognosis than female, especially in cases with positive nodes at diagnosis. Elderly MBC patients have often larger tumors in more advanced stages at the time of diagnosis compared with younger patients. In spite of the advanced tumors at presentation, older patients present often cancers with more favorable biological characteristics, but they receive less guideline-concordant curative treatments (as adequate lymph node staging or adjuvant radiation therapy) compared to women. Moreover, racial differences in treatment of older MBC were observed. Therapeutic management of MBC in elderly patients is a subject rarely addressed in literature. Our review highlighted differences in the treatment and in guidelines-concordance for elderly MBC patients. Adequate geriatric assessment and use of therapeutic schemes adapted to age and comorbidities can avoid under/overtreatment, contributing to a better standard of care in this frail population.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"120-134"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality End-of-Life Cancer Care: An Unfulfilled but Achievable Imperative.

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-02-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01618-2

Guy B Faguet

{"title":"Quality End-of-Life Cancer Care: An Unfulfilled but Achievable Imperative.","authors":"Guy B Faguet","doi":"10.1007/s11912-024-01618-2","DOIUrl":"10.1007/s11912-024-01618-2","url":null,"abstract":"Background: Disease-focus management of late-stage cancer without addressing patients' preferences or quality of life (QoL) can lead to unsatisfactory patient and disease outcomes.Methods: A PRISMA-adherent systematic review of the literature was conducted via PubMed, Embase, Scopus, and Google Scholar to assess the current late-stage cancer treatment modality, setting, timing, and cost, their impact on patient and disease outcomes, and possible interventions for improvement.Results: Out of many studies, twelve from North America, Western Europe, and Asia met our inclusion criteria. A detailed analysis of the 929,408 late-stage cancer patients included revealed common management practices. Typically, patients were subjected to sustained intensive disease-focused treatment through the end-of-life (EoL) while deferring palliative care and other host-sustaining measures. Such practices compromised patients' QoL and increased costs without meeting their needs and expectations or significantly altering the course of the disease. To forestall such practices, five pragmatic host-focused management principles are proposed. In contrast to clinical practice guidelines (CPG), they can be promoted directly to current and future cancer care professionals as an easy-to-memorize and apply template: to the former via continuing medical education, podcasts, webinars, and other tutorials; to the latter by its incorporation into Oncology, Hematology, Hospice, and other cancer-training programs.Conclusions: Despite major advances in early-stage cancer treatment and survival, late-stage cancer care is hindered by continuous disease-focused practices pursued through the EoL that lead to unsatisfactory patient and disease outcomes. Such practices can be reversed by adopting host-focused management principles that promote QoL and meet patients' needs and expectations as a basis for delivering holistic cancer care through the EoL.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"112-119"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oligometastatic Esophagogastric Cancer: Does It Exist and How Do We Treat It? 少转移性食管胃癌：存在吗？我们该如何治疗？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01625-3

Tiuri E Kroese, Sebastiaan F C Bronzwaer, Peter S N van Rossum, Hanneke W M van Laarhoven, Richard van Hillegersberg

{"title":"Oligometastatic Esophagogastric Cancer: Does It Exist and How Do We Treat It?","authors":"Tiuri E Kroese, Sebastiaan F C Bronzwaer, Peter S N van Rossum, Hanneke W M van Laarhoven, Richard van Hillegersberg","doi":"10.1007/s11912-024-01625-3","DOIUrl":"10.1007/s11912-024-01625-3","url":null,"abstract":"Purpose of the review: This narrative review aims to provide an overview of recently completed randomized trials and expert consensus recommendations, and their implications for clinical practice and future trial design in patients with de-novo esophagogastric oligometastatic disease (OMD).Recent findings: The IKF-575/RENAISSANCE phase III trial showed no significant overall survival difference between systemic therapy alone and systemic therapy combined with local therapy for patients with gastric or gastroesophageal junction cancer and de-novo OMD, except for patients with retroperitoneal lymph node metastases only. The ESO-Shanghai 13 phase II trial demonstrated superiority of adding local therapy to systemic therapy for progression-free and overall survival in oligometastatic esophageal squamous cell carcinoma. The OMEC project developed a multidisciplinary European consensus for OMD, proposing a restrictive definition of OMD. Clinical trial assessing the optimal treatment of care are urgently needed. The findings highlight the importance of strict patient selection for local metastasis-directed treatment and the need for stratifying patients based on histology and location of metastases. Future research should focus on identifying biomarkers and clinical features to guide multidisciplinary treatment approaches for OMD.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"30-36"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11762669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The State of Psychosocial Oncology Research on Black Canadian Affected by Cancer: A Scoping Review. 加拿大黑人癌症患者的社会心理肿瘤研究现状：范围综述

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01621-7

Ghizlène Sehabi, Wardat Yasmine Sehabi, Emma Kearns, Celeste Holy, Alanna K Chu, Lauriane Giguère, Patrick R Labelle, Jude Mary Cénat, Sophie Lebel

{"title":"The State of Psychosocial Oncology Research on Black Canadian Affected by Cancer: A Scoping Review.","authors":"Ghizlène Sehabi, Wardat Yasmine Sehabi, Emma Kearns, Celeste Holy, Alanna K Chu, Lauriane Giguère, Patrick R Labelle, Jude Mary Cénat, Sophie Lebel","doi":"10.1007/s11912-024-01621-7","DOIUrl":"10.1007/s11912-024-01621-7","url":null,"abstract":"Purpose of review: This study aims to examine the current state of psychosocial oncology (PSO) research concerning Black Canadian communities, focusing on their experiences, psychological states, and non-biological aspects of their cancer journey.Recent findings: Although there has been increased attention to PSO in the past two decades, there remains a lack of studies specifically addressing the experiences of Black Canadians affected by cancer. This is especially concerning considering the disparities identified by PSO researchers among Black individuals in the United States and the acknowledged health inequities affecting Black individuals in Canada. This scoping review identified a total of five studies that highlighted the significance of religion and spirituality in coping with cancer among Black individuals. While faith emerged as a crucial source of strength, there was notable hesitation to discuss religious beliefs in mainstream support settings. Additional barriers, including stigma surrounding cancer, transportation issues, and limited access to care, further complicated their healthcare experiences. This review reveals critical gaps in research regarding the PSO experiences of Black Canadians affected by cancer and underscores the urgent need for additional studies and the development of tailored support programs to address their unique psychosocial needs and barriers to care.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1-14"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic Role of Long Non-coding RNAs in Multiple Myeloma. 长链非编码rna在多发性骨髓瘤中的表观遗传作用。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01623-5

Nikita Mehra, Subhiksha Sundaram, Parth Shah, Arunagiri Kuha Deva Magendhra Rao

{"title":"Epigenetic Role of Long Non-coding RNAs in Multiple Myeloma.","authors":"Nikita Mehra, Subhiksha Sundaram, Parth Shah, Arunagiri Kuha Deva Magendhra Rao","doi":"10.1007/s11912-024-01623-5","DOIUrl":"10.1007/s11912-024-01623-5","url":null,"abstract":"Purpose of the review: This review aims to explore the pivotal role of long non-coding RNAs (lncRNAs) as epigenetic regulators in the pathogenesis of multiple myeloma (MM). Additionally, we have portrayed the dual role of lncRNAs in the epigenetic landscape of MM pathobiology.Recent findings: In MM, lncRNAs are pivotal for proliferation, progression, and drug resistance by acting as miRNA sponges, regulating mRNA activity through microRNA recognition elements (MREs). Epigenetic modifications in lncRNAs influence gene expression, with some like MEG3, GAS5, CRNDE, and H19 showing promoter hypermethylation, while MALAT1 exhibits hypomethylation. Targeting lncRNAs using siRNA, ASO, CRISPR-Cas9, or small molecule inhibitors shows promise in preclinical studies, alongside the potential benefits of epigenetic-based therapies such as DNMTi and HDACi. Clinical trials combining epigenetic modifiers with standard chemotherapy show encouraging results, especially in relapsed/refractory MM. The key finding of the studies highlighted in the review paves the way for understanding the epigenetic role of lncRNAs in MM disease progression and biology. In addition, the novel therapeutic strategies that have shown promising results have been highlighted. The adoption of the epigenetic landscape into therapeutics in addition to existing treatment strategies may increase the efficacy of treatment approaches.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"37-44"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials. 微生物组和饮食对癌症检查点免疫治疗反应的作用：临床试验的叙述性回顾。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01622-6

Lone Gamrath, Tobias Bruun Pedersen, Martin Vad Møller, Lone Marie Volmer, Linda Holst-Christensen, Lene Weber Vestermark, Frede Donskov

{"title":"Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials.","authors":"Lone Gamrath, Tobias Bruun Pedersen, Martin Vad Møller, Lone Marie Volmer, Linda Holst-Christensen, Lene Weber Vestermark, Frede Donskov","doi":"10.1007/s11912-024-01622-6","DOIUrl":"10.1007/s11912-024-01622-6","url":null,"abstract":"Purpose of review: The advent of checkpoint immunotherapy has dramatically changed the outcomes for patients with cancer. However, a considerable number of patients have little or no response to therapy. We review recent findings on the connection between the gut microbiota and the immune system, exploring whether this link could enhance the effectiveness of immunotherapy.Recent findings: Clinical studies have reported specific types of bacteria in larger quantities at baseline in responders than in non-responders, especially Akkermansia mucinifila, Ruminococcaceae, Faecalibacterium, and Lachnospiraceae. Following the consumption of a high-fiber diet, bacteria in the gut ferment dietary fiber to short-chain fatty acids (SCFAs), like acetate, propionate, and butyrate. Some of the SCFAs nurture intestinal epithelial cells, and some enter the bloodstream. Here SCFAs can activate DC8 + cytotoxic T-cells to induce cancer cell death. High fiber intake in the diet was associated with a reduced risk of progression or death during checkpoint immunotherapy. Recent findings demonstrate that high-fiber plant-based diets such as the Mediterranean Diet positively influence the gut microbiota whereas antibiotics and proton pump inhibitors can negatively influence outcomes of cancer immunotherapy by changing the gut microbiota. This narrative review provides evidence of an association between types of bacteria and their metabolites and favorable responses to checkpoint immunotherapy. Prospective clinical trials are needed to determine if diet interventions can improve treatment outcomes.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"45-58"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11762419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights. 人表皮生长因子受体2阳性晚期胃或食管胃腺癌：反思过去获得新的认识

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01626-2

Yu Aoki, Izuma Nakayama, Kohei Shitara

{"title":"Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.","authors":"Yu Aoki, Izuma Nakayama, Kohei Shitara","doi":"10.1007/s11912-024-01626-2","DOIUrl":"10.1007/s11912-024-01626-2","url":null,"abstract":"Purpose of review: Human epidermal growth factor receptor 2 (HER2) is a critical target in advanced gastric cancer (AGC). This review highlights the current treatment landscape, lessons learned from past clinical trials, and prospects for future treatment strategies for HER2-positive AGC.Recent findings: Trastuzumab had been the standard treatment for HER2-positive AGC for a decade, and subsequently, trastuzumab deruxtecan, an antibody-drug conjugate (ADC), emerged with an impressive response. Recently, the addition of pembrolizumab to first-line chemotherapy plus trastuzumab has become a novel standard treatment. Past clinical trials of HER2-targeted therapies, which succeeded in HER2-positive breast cancer but failed in AGC, have deepened our understanding of resistance mechanisms. Based on these results, several clinical trials of novel HER2-targeted therapies, including immunologic approaches such as CAR-T cells and vaccines, are currently ongoing. Circulating tumor DNA is also expected to be a tool for real-time biomarker analysis. Additionally, ADCs with a bystander effect have the potential to expand the scope of HER2-targeted therapies to HER2-expressing, including HER2-low AGC. Learning from past trials, further development of novel HER2-targeted therapies is underway, expanding their scope to HER2-expressing AGC. Meanwhile, selecting optimal treatment is a challenging issue in cases with HER2-low AGC overlapping with other biomarkers like CLDN18.2.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"15-29"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Developments in VHL-Associated Neuroendocrine Neoplasms. vhl相关神经内分泌肿瘤的新进展。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-05 DOI: 10.1007/s11912-024-01631-5

Marina Tsoli, Maria Panagaki, Elisavet Tasouli, Dionysia Kolomodi, Gregory Kaltsas

引用次数: 0

Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing. 乳腺癌中的抗体-药物偶联物：通往生物学知情选择和测序的道路。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-01-01 Epub Date: 2025-01-05 DOI: 10.1007/s11912-024-01628-0

Tess A O'Meara, Paolo Tarantino, Stefania Morganti, Ilana Schlam, Ana C Garrido-Castro, Sara M Tolaney

{"title":"Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.","authors":"Tess A O'Meara, Paolo Tarantino, Stefania Morganti, Ilana Schlam, Ana C Garrido-Castro, Sara M Tolaney","doi":"10.1007/s11912-024-01628-0","DOIUrl":"10.1007/s11912-024-01628-0","url":null,"abstract":"Purpose of review: In this review, we discuss evidence supporting the use of antibody-drug conjugates (ADCs) in breast cancer treatment, describe novel ADCs and combination regimens under development, and examine our current understanding of resistance mechanisms and biomarkers to guide ADC selection and sequencing.Recent findings: Three ADCs have proven benefit in patients with metastatic breast cancer: trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG). There are over two hundred investigational ADCs on the horizon, as pre-clinical studies work to identify novel ADC targets and structures. In this new frontier, translational efforts are underway to personalize the use of ADCs, including refining HER2 quantification and elucidating genetic, epigenetic, and post-translational mechanisms of resistance. ADCs have provided important treatment options for patients with breast cancer. As patients become eligible for more than one ADC, there is an unmet need to identify the appropriate timing and sequence of these therapies to maximize their efficacy.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"68-79"},"PeriodicalIF":4.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0